[go: up one dir, main page]

MX2014001738A - Anticuerpos anti-tie2 y usos de los mismos. - Google Patents

Anticuerpos anti-tie2 y usos de los mismos.

Info

Publication number
MX2014001738A
MX2014001738A MX2014001738A MX2014001738A MX2014001738A MX 2014001738 A MX2014001738 A MX 2014001738A MX 2014001738 A MX2014001738 A MX 2014001738A MX 2014001738 A MX2014001738 A MX 2014001738A MX 2014001738 A MX2014001738 A MX 2014001738A
Authority
MX
Mexico
Prior art keywords
tie2
antibodies
angtopoietin
bind
tie2 antibodies
Prior art date
Application number
MX2014001738A
Other languages
English (en)
Other versions
MX359833B (es
Inventor
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014001738A publication Critical patent/MX2014001738A/es
Publication of MX359833B publication Critical patent/MX359833B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a Tie2 y métodos para utilizar los mismos. De acuerdo con ciertas modalidades de la invención, los anticuerpos son anticuerpos de humano completos que se unen al Tie2 de humano y bloquean la interacción entre Tie2 y uno o más ligandos de Tie2 tales como angiopoyetina 1 (Ang1), angiopoyetina 2 (Ang2), angiopoyetina 3 (Ang3) y/o angiopoyetina 4 (Ang4). Los anticuerpos de la invención son útiles, inter alia, para el tratamiento de enfermedades y trastornos asociados con una o más actividades biológicas de Tie2, incluyendo la angiogénesis.
MX2014001738A 2011-08-19 2012-08-16 Anticuerpos anti-tie2 y usos de los mismos. MX359833B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23
PCT/US2012/051038 WO2013028442A1 (en) 2011-08-19 2012-08-16 Anti-tie2 antibodies uses thereof

Publications (2)

Publication Number Publication Date
MX2014001738A true MX2014001738A (es) 2014-03-27
MX359833B MX359833B (es) 2018-10-12

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001738A MX359833B (es) 2011-08-19 2012-08-16 Anticuerpos anti-tie2 y usos de los mismos.

Country Status (15)

Country Link
US (4) US9017670B2 (es)
EP (2) EP2744827B1 (es)
JP (2) JP6333174B2 (es)
KR (1) KR20140054303A (es)
CN (2) CN106963946A (es)
AR (1) AR087567A1 (es)
AU (1) AU2012299195B9 (es)
CA (1) CA2844306C (es)
ES (1) ES2694411T3 (es)
IL (1) IL230529A (es)
IN (1) IN2014CN02025A (es)
MX (1) MX359833B (es)
SG (1) SG10201606872TA (es)
UY (1) UY34271A (es)
WO (1) WO2013028442A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
CA2844306C (en) 2011-08-19 2022-08-16 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies and uses thereof
AU2014342162B2 (en) * 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
JP6699551B2 (ja) * 2014-07-15 2020-05-27 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
EP3580568A1 (en) 2017-02-09 2019-12-18 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
AU2019283520A1 (en) * 2018-06-07 2021-01-07 Institute For Basic Science Antibody binding to Tie2 and use thereof
WO2020006516A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021029746A2 (ko) * 2019-08-14 2021-02-18 주식회사 파멥신 항-tie2 항체 및 이의 용도
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology ANTIBODIES AGAINST TIE-2 AND METHODS OF USE
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
WO2022225182A1 (ko) * 2021-04-23 2022-10-27 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
GEAP202416581A (en) * 2022-01-13 2024-12-10 Ingenia Therapeutics Inc Vegf and tie2-binding fusion protein and uses thereof
CN115947818B (zh) * 2022-10-25 2024-08-02 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
AU4651893A (en) 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ES2262518T5 (es) 1999-06-07 2009-05-08 Immunex Corporation Antagonistas de tek.
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP2298334A3 (en) * 1999-12-20 2012-04-04 Immunex Corporation Tweak receptor
DE60128685T2 (de) 2000-06-23 2009-03-05 Bayer Schering Pharma Aktiengesellschaft Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
BRPI0511065A (pt) * 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
WO2006005361A1 (en) 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
AU2005272848A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
EP1880993A4 (en) 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd NITROGENIC HETEROCYCLIC COMPOUND
ES2612258T3 (es) 2006-10-27 2017-05-16 Sunnybrook Health Sciences Center Agonistas multiméricos de Tie 2 y usos de los mismos en la estimulación de la angiogénesis
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8685393B2 (en) 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
CA2844306C (en) 2011-08-19 2022-08-16 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies and uses thereof

Also Published As

Publication number Publication date
JP6333174B2 (ja) 2018-05-30
UY34271A (es) 2013-02-28
WO2013028442A1 (en) 2013-02-28
AR087567A1 (es) 2014-04-03
US10442864B2 (en) 2019-10-15
SG10201606872TA (en) 2016-10-28
MX359833B (es) 2018-10-12
EP3415533A1 (en) 2018-12-19
CN106963946A (zh) 2017-07-21
CA2844306A1 (en) 2013-02-28
CN103874709A (zh) 2014-06-18
NZ621481A (en) 2016-04-29
CN103874709B (zh) 2016-12-21
ES2694411T3 (es) 2018-12-20
US20150197578A1 (en) 2015-07-16
IL230529A (en) 2017-07-31
AU2012299195B9 (en) 2018-05-10
US10023641B2 (en) 2018-07-17
IN2014CN02025A (es) 2015-05-29
CA2844306C (en) 2022-08-16
AU2012299195B2 (en) 2018-04-19
JP2014525934A (ja) 2014-10-02
KR20140054303A (ko) 2014-05-08
EP2744827A1 (en) 2014-06-25
JP6654165B2 (ja) 2020-02-26
IL230529A0 (en) 2014-03-31
US20130209492A1 (en) 2013-08-15
US9017670B2 (en) 2015-04-28
US9546218B2 (en) 2017-01-17
EP2744827B1 (en) 2018-10-03
JP2017186347A (ja) 2017-10-12
US20180291105A1 (en) 2018-10-11
US20170088622A1 (en) 2017-03-30
AU2012299195A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
MX359833B (es) Anticuerpos anti-tie2 y usos de los mismos.
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
PH12015501493A1 (en) Anti-pdgfr-beta antibodies and uses thereof
TN2012000434A1 (en) Biparatopic abeta binding polypeptides
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
PH12014500483A1 (en) Anti-erbb3 antibodies and uses thereof
MY191087A (en) Compounds and uses thereof for the modulation of hemoglobin
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
MX2024008826A (es) Composicion para la estimulacion ovarica controlada.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2013011596A (es) Anticuerpos que se unen a tgf-alfa y epiregulina.
TN2014000391A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours

Legal Events

Date Code Title Description
FG Grant or registration